Page URL:

Genomics England forms industry collaboration

30 March 2015
Appeared in BioNews 796

Genomics England has announced a new consortium that will see it share data from the 100,000 Genomes Project with major pharmaceutical industry players.

Ten companies, including GSK, AstraZeneca and Roche, have signed up to be part of the GENE Consortium and, during a trial year, they will receive access to 5,000 genomes sequenced as part of the project and linked patient data.

Genomics England say they aim to identify the best ways to involve industry in the genome sequencing project in order to accelerate the use of its data for new diagnostics and gene-targeted treatments.

Genomics England executive chairman Sir John Chisholm said the organisation was 'delighted' to announce the partnership. 'We are determined that NHS patients will be amongst the first to benefit from the discoveries uncovered by the project.'

He added: 'This year we will explore how companies, clinicians and researchers can work together on the 100,000 Genomes Project - giving us a platform to expand and build upon.'

At present, Genomics England has not revealed any detail about the terms of the deal so it is unclear what financial arrangements have been made and what has been agreed about the use of the data after the trial year.

Recently, critics of the 100,000 Genome Project have expressed concern over the sharing of participants' data with commercial partners. Writing for The Guardian, Edward Hockings and Lewis Coyne found via Freedom of Information requests to the Department of Health that data given to third parties will not be fully anonymised.

Speaking to BioNews, Dr Helen Wallace of GeneWatch UK also criticised the process used to gain consent from participants of the 100,000 Genomes Project, which does not allow them to withhold their data from commercial parties.

'A major concern is that if personalised risk assessments become commercialised these can be distorted in ways that maximise the drug market, rather than improving health,' she told BioNews via email.

'Because of the broad nature of the consent, there is no process for people to consider conflicts-of-interest or decide which companies they might want to access their data for what purposes.'

Genomics England also this week announced a development in its UK-based research collaboration, the Clinical Interpretation Partnership (GeCIP). After inviting applications last November, the company has now selected over 28 teams of researchers who will work on improving diagnosis for a range of conditions. There will also be analytical and social science research covering areas such as ethics, law, health economics and the use of electronic health records.

'We hope that this unique collaboration will lead to earlier and more precise diagnoses for patients and, working with companies, will pave the way for new, more targeted therapies and treatments,' said Genomics England chief scientist Professor Mark Caulfield.

Have your say about whole genome sequencing, by taking a minute to complete the "100,000 Genomes Project Poll" on BioNews here.

Academia, the NHS and industry collaborate on 100,000 genomes project
PharmaTimes |  26 March 2015
Big Pharma joins the U.K.'s genomics project with eyes on drug discovery
Fierce Biotech |  26 March 2015
Biopharmas Team Up with U.K.'s 100,000 Genomes Project
Genetic Engineering & Biotechnology News |  26 March 2015
Clinicians, Researchers and Industry collaborate with the 100,000 Genomes Project
Genomics England |  26 March 2015
Drugs companies unite to mine genetic data
Financial Times |  26 March 2015
31 July 2017 - by BioNews 
This film documents the Progress Educational Trust/Genomics England event 'What Next for Genomics? Providing Answers, Changing Lives, Transforming the NHS', which launched the Chief Medical Officer's report Generation Genome...
10 July 2017 - by Dr Rachel Montgomery 
A packed public event, produced by the Progress Educational Trust in partnership with Genomics England, saw the Chief Medical Officer for England launch her report 'Generation Genome'...
25 April 2016 - by Rachel Siden 
AstraZeneca has signed deals with the Wellcome Trust Sanger Institute and two other institutions to launch one of the largest genome-sequencing efforts yet undertaken...
7 March 2016 - by Antony Starza-Allen 
Genome sequencing in Scotland has received a major cash boost, following a £6 million investment into the Scottish Genomes Partnership (SGP), which will begin working with Genomics England on the 100,000 Genomes Project...
28 September 2015 - by Sarah Pritchard 
Genomics England has produced a short animated film to explain exactly what happens to the data it is collecting as part of the 100,000 Genomes Project. After watching it, I feel that I know exactly where my data would go if I was to take part in the project, and that they would be guarded like the crown jewels...
16 March 2015 - by Dr Hannah Somers 
Three British men have been diagnosed with rare diseases after having their complete genomes sequenced as part of the UK-based 100,000 Genomes Project...
12 January 2015 - by Dr Barbara Kramarz 
Eleven NHS Genomic Medicine Centres have been announced by Genomics England to spearhead the 100,000 Genomes Project...
24 November 2014 - by David O'Rourke 
Genomics England is inviting applications from UK researchers, NHS clinicians and those in scientific training to access the data compiled by its DNA sequencing project, the 100,000 Genomes Project....
4 August 2014 - by Siobhan Chan 
The UK Government has announced it will provide £300 million funding for a project to sequence 100,000 genomes, saying that it will 'revolutionise [the] fight against cancer and rare diseases'...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.